Institute of Human Virology Annual Meeting 2005-2010

人类病毒学研究所2005-2010年年会

• 批准号: 7087025
• 负责人: ROBERT C GALLO
• 金额: $ 4.6万
• 依托单位: UNIVERSITY OF MD BIOTECHNOLOGY INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-08-18 至 2007-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7087025
• 关键词: AIDS; AIDS related neoplasm /cancer; health science research potential; information dissemination; meeting /conference /symposium; minority health professional; travel

For nine years the International Meeting of the Institute of Human Virology (Meeting) has provided a forum for dedicated scientists in the fields of virology, most specifically HIV/AIDS and cancer biology to present new data and exchange ideas and views. The Meeting serves as a unique conference with the following aims: 1. To disseminate the most current research findings within the selected program topics; 2. To critically assess the impact of new findings on future directions for research; 3. To provide a forum for discussion of current and emerging issues; 4. To identify, support, and build the next generation AIDS researcher; 5. To increase participation by women ethnic/racial minorities, and other individuals who have been traditionally under represented in science, yet over represented in the populations impacted most by the disease and to increase participation by individuals from the developing world. The Institute of Human Virology (EHV), with the financial support requested in this application, will accomplish these aims: a) by attracting world renown senior scientists as presenters and participants; b) by carefully organizing each dedicated conference session with theoretically divergent perspectives and ethnically diverse participants; c) by enriching the scientific sessions with an open schedule to foster dialog and interaction between and among investigators; d) by reaching out to and promoting the participation of young investigators in poster sessions and scholarship initiatives, and e) by ensuring that conference results are shared with the broader scientific community through publication of all speaker and poster abstracts. The Meeting is further strengthened by a strictly enforced press policy, one that protects data presented at the Meeting for future peer-reviewed publication. This policy prohibits the members of the press from disclosing any information presented at the Annual Meeting without the permission of the presenter. An estimated 650 scientists and clinicians from around the world are expected to participate in this five-day meeting scheduled for August 29 - September 2, 2005 at the Baltimore Waterfront Marriott. To increase participation by FDA and NIH scientists the meetings in 2006-2009 will be alternate between Bethesda and Baltimore in suitable locations. The Meeting for 2005 will offer a combination of single track and dual track lectures. The incorporation of dual track sessions is a result of feedback from our participants who like some of the more specialized sessions that may not be of interest to the entire group but may not be topics at more general meetings they attend including topics like HTLV. This change also allows for more time to be set aside for oral presentations selected from a call for abstracts. Each conference session opens with a senior scientist's overview presentation on the current base of knowledge in the topic of discussion. This overview provides a basis for evaluation of the data presented by a panel of speakers, each sharing the results of their work. The Annual Meeting Program Committee, responsible for the program content, is encouraged to invite speakers with differing perspectives to stimulate open discussion. Posters are displayed throughout the meeting. One evening is set aside for a reception in the poster area to encourage attendance and interaction. Evening social events are provided to encourage participants to meet with current and potential collaborators, and to talk with presenters. The Annual Meeting Scholarship Initiative provides funds to ensure the participation of promising women, ethnic and racial minorities, and other individuals who have been traditionally underrepresented in science as well as participants from the developing world.

九年来，人类病毒学研究所国际会议（会议）为病毒学领域，特别是艾滋病毒/艾滋病和癌症生物学领域的专门科学家提供了一个论坛，以展示新数据并交流想法和观点。本次会议是一次独特的会议，其目标如下： 1. 传播所选项目主题内的最新研究成果； 2. 批判性地评估新发现对未来研究方向的影响； 3. 提供讨论当前和新出现问题的论坛； 4. 识别、支持和培养下一代艾滋病研究人员； 5. 增加族裔/种族少数妇女以及传统上在科学领域代表性不足、但在受疾病影响最严重的人群中代表性过高的其他个人的参与，并增加来自发展中国家的个人的参与。 人类病毒学研究所 (EHV) 在本申请中要求的财政支持下，将实现以下目标： a) 吸引世界知名的资深科学家作为演讲者和参与者； b) 精心组织每一次专门的会议，具有不同的理论观点和不同种族的参与者； c) 通过开放的时间表丰富科学会议，以促进研究者之间的对话和互动； d) 通过接触并促进年轻研究者参与海报会议， 奖学金倡议，以及 e) 通过出版所有演讲者和海报摘要，确保与更广泛的科学界共享会议结果。严格执行的新闻政策进一步加强了会议的力量，该政策保护会议上提交的数据以供未来同行评审出版物使用。该政策禁止新闻界人士未经大会许可披露在年会上提出的任何信息 主持人。预计将有来自世界各地的 650 名科学家和临床医生参加定于 2005 年 8 月 29 日至 9 月 2 日在巴尔的摩海滨万豪酒店举行的为期五天的会议。为了增加 FDA 和 NIH 科学家的参与，2006-2009 年的会议将在贝塞斯达和巴尔的摩在适当的地点轮流举行。 2005年会议将采取单轨和双轨相结合的方式进行。双轨会议的合并是我们参与者反馈的结果，他们喜欢一些更专业的会议，这些会议可能不是整个小组感兴趣的，但可能不是他们参加的更广泛的会议的主题，包括 HTLV 等主题。这 变化还允许留出更多时间用于从摘要征集中选出的口头陈述。每场会议均以资深科学家对讨论主题的当前知识基础进行概述性介绍开始。该概述为评估发言人小组提供的数据提供了基础，每个发言人都分享了他们的工作成果。年会程序委员会，负责程序内容，鼓励 邀请具有不同观点的演讲者来激发公开讨论。会议期间张贴海报。安排一个晚上在海报区举办招待会，以鼓励出席和互动。提供晚间社交活动，以鼓励参与者与当前和潜在的合作者会面，并与演讲者交谈。年会奖学金计划提供资金，以确保有前途的妇女、少数族裔和种族以及传统上在科学领域代表性不足的其他个人以及来自发展中国家的参与者的参与。